A Focus on Cellular Therapies.png

Friday, May 22, 2026 |11 a.m.–3 p.m. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of cellular therapies, including CAR T cell, T cell receptor (TCR), and TIL therapies. FREE for healthcare professionals, students, patients and patient advocates. 

New for 2026

  • Presentations on trials of next generation approaches with cellular therapies, including TCR T cells and current trials of combination approaches that include cellular therapies.

  • Review novel cellular therapy constructs, such as logic-gated CAR T cells and in vivo CAR T cells.

  • Address logistics and toxicities associated with TIL therapy and with CAR T cells.

Program Organizers

Amaria, Rodabe

Rodabe Amaria, MD
MD Anderson Cancer Center

Nathan Denlinger, DO, MS 

Nathan Denlinger, DO, MS 
The Ohio State University Comprehensive Cancer Center

Michael Hurwitz, MD

Michael Hurwitz, MD
Yale School of Medicine

Program Agenda

11 – 11:05 a.m. Welcome
11:05 – 11:25 a.m. CAR T for Hematologic Malignancies – CD19 
11:25 – 11:45 a.m. CAR T for Hematologic Malignancies – BCMA
Karina Patel MD, MSc - MD Anderson Cancer Center
11:45 a.m. – 12:15 p.m. TILs 
12:15 – 12:40 p.m. Future Therapies, Current Trials, and Combinations for Solid Tumors 
12:40 – 1:05 p.m. Novel Cell Therapy Constructs 
1:05 – 1:20 p.m. Break 
1:20 – 1:40 p.m. Cancer Immunotherapy in Practice: Logistics and Toxicities of TILs 
Alison Betof, MD, PhD - Stanford University School of Medicine 
1:40 – 2 p.m. Cancer Immunotherapy in Practice: Logistics and Toxicities of CAR T 
Krish Patel, MD - Sarah Cannon Research Institute
2 – 3 p.m. Faculty Panel 
3 p.m. Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to onlineeducation@sitcancer.org.

Program Learning Objectives

  • Describe the mechanisms of cellular therapies, including TIL therapies.
  • Summarize recent updates in the clinical use of cell therapies, including the recent approvals of cellular therapies for solid tumors.
  • Outline common toxicities with the different cell therapies and common approaches to managing these toxicities.
  • Identify unique institutional resources required for the appropriate use of cell therapies, including TIL therapy.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education and the Society for Immunotherapy of Cancer (SITC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

Partners designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Partners designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

The 2026 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.

Partners for Advancing Clinical Education Logo

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.